fda and compounded glp 1 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our 🚨 FDA Commissioner Signals Swift

You can track this in a spreadsheet, a notes app, or a paper journal

PLoS One 9:e107174 Kasuki L, Antunes X, Lamback EB, Gadelha MR (2020) Acromegaly: update on management and long-term morbidities

Numerous case reports of adverse events with GLP-1 agonists have been published over the last two years

This process will involve careful review of safety and efficacy by the FDA and other global agencies, and decisions about how and when the drug can be prescribed

The diagnostic accuracy of one-step nucleic acid amplification for lymph node metastases of papillary thyroid carcinoma: A systematic review and meta-analysis